Home

Eli Lilly (LLY)

798.89
+22.45 (2.89%)
NYSE · Last Trade: Jul 23rd, 10:59 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close776.44
Open780.00
Bid797.00
Ask797.50
Day's Range777.08 - 800.09
52 Week Range677.09 - 972.53
Volume2,683,559
Market Cap764.20B
PE Ratio (TTM)65.00
EPS (TTM)12.3
Dividend & Yield6.000 (0.75%)
1 Month Average Volume2,887,285

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Healthcare Stocks Hit Valuation Bottom, 3 Names to Reboundmarketbeat.com
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside
Via MarketBeat · July 23, 2025
Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costsbenzinga.com
Via Benzinga · July 23, 2025
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Resultsinvestors.com
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.
Via Investor's Business Daily · July 23, 2025
2 Vanguard ETFs That Can Turn $400 per Month Into Over $1.7 Millionfool.com
Exchange-traded funds (ETFs) can be a lucrative source of wealth for patient investors.
Via The Motley Fool · July 23, 2025
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To USbenzinga.com
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via Benzinga · July 22, 2025
Better Growth Buy: Eli Lilly vs. Viking Therapeuticsfool.com
Via The Motley Fool · July 22, 2025
2 Beaten-Down Dividend Growth Stocks to Buy on the Dipfool.com
Via The Motley Fool · July 22, 2025
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Resultsfool.com
Via The Motley Fool · July 22, 2025
5 Monster Stocks to Hold for the Next 25 Yearsfool.com
Buy-and-hold investing only works if you choose the right companies. Here are some potential examples.
Via The Motley Fool · July 22, 2025
AstraZeneca Bets Big On America With $50B Investment, New Virginia Hub Plans Amid Pharma Tariff Jittersstocktwits.com
At the center of the company’s plan is a new, multi-billion-dollar manufacturing facility in Virginia.
Via Stocktwits · July 21, 2025
Should You Invest in This Under-the-Radar Weight Loss Stock?fool.com
Via The Motley Fool · July 21, 2025
Here's Why Vanguard's Worst-Performing Sector ETF Is a No-Brainer Buy Right Nowfool.com
Via The Motley Fool · July 21, 2025
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.fool.com
Via The Motley Fool · July 20, 2025
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.fool.com
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Via The Motley Fool · July 19, 2025
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?fool.com
Via The Motley Fool · July 18, 2025
Top S&P500 movers in Thursday's sessionchartmill.com
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · July 17, 2025
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Offbenzinga.com
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery.
Via Benzinga · July 17, 2025
Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aislesbenzinga.com
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns.
Via Benzinga · July 17, 2025
1 Volatile Stock with Exciting Potential and 2 to Question
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.
Via StockStory · July 17, 2025
WeightWatchers (WW) Stock Trades Up, Here Is Why
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company successfully completed its strategic reorganization process and announced new program innovations. 
Via StockStory · July 16, 2025
What's going on in today's session: S&P500 moverschartmill.com
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · July 16, 2025
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · July 16, 2025
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'benzinga.com
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via Benzinga · July 16, 2025
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlookmarketbeat.com
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
Via MarketBeat · July 15, 2025
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.
Via AB Newswire · July 15, 2025